重大事件
即時報告
8-K
2026-06-04
AN2 Therapeutics提交8-K，披露監管更新及臨床試驗進展
AI 繁中摘要
AN2 Therapeutics, Inc.（納斯達克代碼：ANTX）於2026年6月4日向美國證監會（SEC）提交了一份8-K表格，主要涵蓋兩項披露：Item 7.01（Regulation FD Disclosure）及Item 8.01（Other Events），並隨附Item 9.01的財務報表與附件。本文件暫未列出具體財務數字或季度業績，核心內容見於附件99.1（EX-99.1）新聞稿或投資者簡報。作為一家專注藥物研發的生物製藥公司（SIC 2834），該8-K通常涉及臨床試驗進展、監管更新或合作協議等重大消息。投資者應仔細閱讀附件以了解事件全貌，該披露可能對短期股價或市場預期產生影響。目前尚未公佈具體金額或利潤展望，建議持續跟蹤公司後續公告。
展開英文正文
EDGAR Filing Documents for 0001193125-26-257430 SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K - Current report: SEC Accession No. 0001193125-26-257430 Filing Date 2026-06-04 Accepted 2026-06-04 16:15:49 Documents 12 Period of Report 2026-06-04 Items Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K d247428d8k.htm iXBRL 8-K 38184 2 EX-99.1 d247428dex991.htm EX-99.1 22756 Complete submission text file 0001193125-26-257430.txt 191613 Data Files Seq Description Document Type Size 3 XBRL TAXONOMY EXTENSION SCHEMA antx-20260604.xsd EX-101.SCH 3201 4 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20260604_lab.xml EX-101.LAB 18735 5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20260604_pre.xml EX-101.PRE 11721 15 EXTRACTED XBRL INSTANCE DOCUMENT d247428d8k_htm.xml XML 3761 Mailing Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 Business Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 (650) 331-9090 AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings) EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 261065182 SIC: 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)